A missed endpoint in the pivotal trial of its sole candidate sent shares of Evoke Pharma Inc. (NASDAQ:EVOK) down 73.1 percent to close at $2.89 on Monday as the company's nasal formulation of the proven diabetic gastroparesis drug metoclopramide, EVK-001, failed to achieve its primary endpoint of improving symptoms at week four of the all-female study.